Results 151 to 160 of about 83,236 (262)
Tissue Resident Memory Cells: Friend or Foe?
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude +2 more
wiley +1 more source
Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints. [PDF]
Rodriguez Rosario AE +17 more
europepmc +1 more source
Natural Killer (NK) cells are potent effectors against virus‐infected and tumour cells. During Friend Virus (FV) infection, fatty acid metabolism supports NK‐cell effector functions. Here, we found that NK cells from FV‐infected mice preferentially take up linoleic acid (LA), which reduced proliferation, mitochondrial function, and increased reactive ...
Vaasudevan Sridhar +8 more
wiley +1 more source
Clinical and genetic features of CTLA-4 haploinsufficiency: a prospective study in China. [PDF]
Liu G +5 more
europepmc +1 more source
Determinants of T Cell Exhaustion: How Far Back Can We Go?
Classical versus Emerging models of CD8+ T Cell Exhaustion. Comparison of the classical ‘Endpoint Model’ (Left), where exhaustion is viewed as a terminal state requiring reversal, versus the emerging ‘Trajectory Model’ (Right). Recent studies suggest exhaustion is a continuous developmental path initiated early in infection or tumuorigenesis ...
Testimony Olumade +2 more
wiley +1 more source
Oral lichenoid lesions in CTLA-4 haploinsufficiency: Targeting IFN-γ-driven mucosal immunopathology. [PDF]
Wang C +11 more
europepmc +1 more source
Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer +11 more
wiley +1 more source
Design and Characterization of Prodrugged Anti-CTLA-4 Antibodies. [PDF]
Yamazoe S +15 more
europepmc +1 more source
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma +36 more
wiley +1 more source
UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer. [PDF]
Hong X +7 more
europepmc +1 more source

